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CASE LETTERSFig 1. Plasmacytoma. Sagittal T1-weighted magnetic reso-
nance imaging scan demonstrating tumor invasion
through left frontal bone.
Fig 2. Diffuse infiltration of plasma cells with character-
istic round oval cells, eccentric nuclei, and moderate
cytoplasm. (Hematoxylin-eosin stain.)Extraosseous extension of multiple myeloma:
A cutaneous herald to systemic disease
To the Editor: Cutaneous involvement of multiple
myeloma is an extremely rare manifestation, typi-
cally presenting as an extraosseous extension to the
skin.1 Presentation of these cutaneous lesions
occurs more often in late stage multiple myeloma
with a high tumor burden.2 A single-center retro-
spective study reported a 2.3% incidence of extra-
medullary and extraosseous tumor at the time of
multiple myeloma diagnosis. Furthermore, cuta-
neous appearance and histopathology do not pre-
dict systemic disease and should alert the
dermatologist to a need for further evaluation.3
We report a case of multiple myeloma presenting as
an extraosseous extension mimicking a cutaneous
mass. A previously healthy 62-year-old woman
presented with an asymptomatic left forehead
mass of 1 month’s duration. On examination, the
3.5- to 4-cm mass was nontender and nonfixed, and
appeared subcutaneous. Two days later, the patient
presented for excision of the left forehead mass.
Blunt dissection uncovered a deeper subfrontalis
grayish mass that was slightly firm and 3.5 to 4 cm in
diameter. Careful dissection at the periosteal plane
of the left frontal bone demonstrated a ragged
1.5-cm outer table bony defect. Biopsy specimen
of the mass was obtained and the wound was
closed. Because of the potential for intracranial
involvement, the patient was sent for immediate
magnetic resonance imaging (MRI) of the left fron-
tal soft tissue bone and brain (Fig 1). The MRI scan
revealed a large expansile enhancing mass anteri-
orly in the left frontal bone and several smaller
enhancing masses in the calvarium. Pathology of
the biopsy specimen revealed a monomorphous
proliferation of medium to large neoplastic-
appearing plasma cells, strongly positive for
CD138, CD38, and lambda light chain, but negative
for kappa light chain (Fig 2). Lambda-positive
cutaneous plasmacytoma was diagnosed and the
patient was referred to an oncologist for further
workup. Bone marrow biopsy demonstrated a 50%
cellular bone marrow comprised of approximately
25% plasma cells, all with a 46XX karyotype.
Subsequent computed tomography and positron
emission tomography scan showed osseous lesions
in the axial and appendicular skeletons, lytic lesions
in the skull and distal right humerus, multiple rib
fractures, and scattered lucent lesions in theJ AM ACAD DERMATOL Open access under CC BY-NC-ND license.bilateral third ribs, left fifth rib, right seventh rib,
and left clavicle. Lambda light chainrestricted
multiple myeloma was ultimately diagnosed. She
underwent initial radiotherapy to the forehead,
followed by aggressive induction chemotherapy
with lenalidomide and dexamethasone. Eight
months after her initial dermatologic presentation,
the patient underwent stem cell collection followed
by high-dose melphalan autologous stem cell trans-
plantation. She recovered all cell counts following
the transplant and was maintained on prophylactic
antimicrobials per protocol. A 15-month course ofSEPTEMBER 2014 e73
Fig 1. Phototesting in a patient with solar urticaria
following light-emitting diode therapy. Erythema and
edema were observed 5 minutes after exposure to visible
light (left) and 415 nm blue light (right).
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e74 Letterslenalidomide maintenance therapy was initiated in
addition to zoledronic acid at tri-monthly intervals
for the prevention of skeletal fractures. At her
3-month bone marrow biopsy and 1-year follow-
up following stem cell transplantation, the patient
continued to be in a stringent complete first
response. She continues to tolerate maintenance
treatment well and follows up with her oncologist
intermittently.
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http://dx.doi.org/10.1016/j.jaad.2014.01.887Solar urticaria to visible light triggered by
light-emitting diode therapy
To the Editor: Light Emitting Diodes (LEDs) are
increasingly used for many conditions, including
wound healing and treatment of photoaging skin.
They are said to be a safe procedure without side
effects. We report a case of solar urticaria to visible
light induced by LED therapy.
A 55-year-old woman with no history of urticarial
rash following previous sun exposures was treated
with a 415-nm LED for mild rosacea. During the LED
exposure an intense urticarial reaction of the face
with burning sensation developed on her face
necessitating discontinuation of the session. There
were no concomitant respiratory or digestive
symptoms. Following this session, she reported a
photosensitivity that impaired her quality of life, andshe was referred to our department. Results of
routine laboratory blood studies were normal,
including antinuclear antibodies and porphyrin
levels. The patient was phototested in the solar UV
domain using a solar simulator (Oriel Newport,
model 92292, high-pressure Xenon lamp) with a
WG320/1.6 mm and UG11/1 mm filter combination
(no visible light emitted). Phototests in UVB and UVA
spectrum (exposure to six increasing doses, from
9.2 mJ/cm2 to 28.2 mJ/cm2) and UVA spectrum alone
(33 J/cm2) did not induce any abnormal reaction. On
the contrary, explorations using total visible light
(ultra-high-pressure mercury lamp, 126 J/cm2) as
well as blue light (wavelength 415 nm, 42.3 J/cm2)
induced an erythematous and edematous reaction at
the end of exposure, with itching and burning
sensations (Fig 1). Thus, phototesting confirmed
the diagnosis of solar urticaria to visible light induced
by blue LED therapy. Antihistamines combined with
hydroxychloroquine and use of a broad-spectrum
sunscreen did not improve the solar urticaria.
A desensitization phototherapy, according to a
well-defined protocol,1 allowed a marked regression
of the symptoms.
Initially used for their healing properties, LEDs
have many well demonstrated biological effects
in vitro that suggest they have potential therapeu-
tic value. However, it is difficult to extrapolate
these in vitro data to clinical practice because
many factors must be taken into consideration,
such as wavelength, irradiance, and the interac-
tion with whole human skin.2 Unfortunately,
except in cases of wound healing, clinical studies
of good methodology are lacking.3,4 Despite the
absence of clinical evidence, use of LEDs is
becoming increasingly popular. Their safety pro-
file is described as excellent in the literature; only
cautions concerning epileptic and photophobic
